Method of treating cancer with an anti-CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8
The present invention provides a pharmaceutical composition for cancer treatment comprising an antibody against CCR8.
1. A method for treating a cancer in a patient having cancer, said method comprising:
administering to the patient in a therapeutically effective amount an IgG antibody against CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8, wherein the antibody against CCR8 binds to CCR8 on tumor-infiltrating Treg cells or tumor-infiltrating macrophage cells, and removes these cells by the ADCC activity of this antibody,
wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, kidney cancer, and sarcoma, and
wherein in the administering step, the only antibody administered is the IgG antibody against CCR8.
2. The method according to claim 1 , wherein the antibody against CCR8 is a CCR8-neutralizing antibody.
3. The method according to claim 1 , wherein the cancer is breast cancer.
4. The method according to claim 1 , wherein the cancer is colorectal cancer.
5. The method according to claim 1 , wherein the cancer is kidney cancer.
6. The method according to claim 1 , wherein the cancer is sarcoma.
7. The method according to claim 1 , comprising further administration of an anti-PD-1 antibody or an anti-PD-L1 antibody.
8. The method according to claim 7 , wherein the cancer is breast cancer.
9. The method according to claim 7 , wherein the cancer is colorectal cancer.
10. The method according to claim 7 , wherein the cancer is kidney cancer.
11. The method according to claim 7 , wherein the cancer is sarcoma.
12. The method according to claim 1 , wherein an Fc region of the antibody is free from a fucose bound with N-acetylglucosamine.
13. The method according to claim 1 , wherein the antibody is administered as a composition further comprising a carrier.
14. The method according to claim 13 , wherein the composition is administered at a dose of 10 to 500 mg.
15. The method according to claim 14 , wherein the composition is administered intravenously.
16. The method according to claim 14 , wherein the composition is administered intraperitoneally.
17. A method for treating cancer in a patient having cancer, said method comprising:
administering to the patient in a therapeutically effective amount an IgG antibody against CCR8 having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8,
wherein the EC50 value of FcγR activation by the antibody is approximately 0.1 μg/ml, wherein the EC50 value is a result of ADCC assays by mixing CCR8-expressing HEK293 target cells and FcγR-expressing effector cells at a ratio of 1:1.5,
wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, kidney cancer, and sarcoma, and
wherein in the administering step, the only antibody administered is the IgG antibody against CCR8.
18. The method according to claim 17 , wherein the antibody against CCR8 is a CCR8-neutralizing antibody.
19. A method for treating a cancer in a patient having cancer, said method comprising:
administering to the patient in a therapeutically effective amount an IgG antibody 1) capable of binding CCR8 on the surface of tumor-infiltrating Treg cells or tumor-infiltrating macrophage cells and 2) having antibody-dependent cell-mediated cytotoxicity (ADCC) activity against cells expressing CCR8,
wherein the cancer is selected from the group consisting of colorectal cancer, breast cancer, kidney cancer, and sarcoma, and
wherein in the administering step, the only antibody administered is the IgG antibody against CCR8.
20. The method according to claim 19 , wherein the cancer is breast cancer.
21. The method according to claim 19 , wherein the cancer is colorectal cancer.
22. The method according to claim 19 , wherein the cancer is kidney cancer.
23. The method according to claim 19 , wherein the cancer is sarcoma.
24. The method according to claim 19 , wherein an Fc region of the antibody is free from a fucose bound with N-acetylglucosamine.
25. The method according to claim 19 , wherein the antibody is administered as a composition further comprising a carrier.
26. The method according to claim 25 , wherein the composition is administered at a dose of 10 to 500 mg.
27. The method according to claim 25 , wherein the composition is administered intravenously.
28. The method according to claim 25 , wherein the composition is administered intraperitoneally.